Expand into Europe: unlocking the orphan drug market
The European orphan drug market is growing rapidly, offering U.S. biotech companies a significant opportunity for expansion. However, navigating the region’s complex regulatory, pricing, and reimbursement landscapes requires a strategic approach.
In this exclusive guide, we cover:
- Key regulatory pathways and market entry considerations for orphan drugs in Europe
- How to leverage early access programs and real-world data for market adoption
- The benefits of partnering with European specialists to streamline distribution and compliance
- Best practices for patient engagement, advocacy, and long-term market success
Download this guide to learn how to successfully commercialize your orphan drug in Europe, ensuring both patient impact and commercial viability.
About Sciensus
Sciensus is a proven life sciences solutions partner with more than 30 years’ experience in navigating and unlocking the complex European healthcare ecosystem to maximise patient reach. We help accelerate the development journey, bringing medicines into the market and directly to patients to improve health outcomes. Through cutting-edge patient engagement programmes, offering an exclusive combination of skilled in-person care and digital support, we help patients make the most of their treatment and generate real-world evidence that can be used to improve treatment pathways.
Read more on…
Blogs
How Biotechs can expand in Europe: Out-licensing vs. partnering
Out-licensing, partnering or going it alone. What is the best strategy to access Europe? Many US biotech and pharma companies…
Thought Leadership
EU orphan drug roll out: navigating regulatory challenges
Blogs
Planning your EU orphan drug stock management with Sciensus
Launching an orphan drug across multiple European Union (EU) countries is a complex task that requires careful planning and execution.…